Compare Baidu Inc (BIDU) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baidu Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Baidu Inc trades at $112.7 (market cap $36.80B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.71 (market cap $8.04B). The key difference: Baidu Inc is far larger — about 4.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| BIDU | BIO | |
|---|---|---|
Market Cap | $36.80B | $8.04B |
Sector | Media | Health |
52-Week High | $162.52 | $339.75 |
52-Week Low | $85.86 | $241.71 |
Enterprise Value | $33.45B | $7.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $113.39, down 3.52% amid bearish technical signals and mixed fundamentals. The stock faces pressure from declining revenue and net income margins, though it maintains strong analyst support with a $161 consensus price target. Recent news highlights AI optimism from Kunlunxin's potential $50 billion Hong Kong IPO, while cash flow trends show significant investing outflows. Technical indicators show bearish moving averages with neutral oscillators, trading near key support at $112.
Baidu presents a high-risk opportunity with Wall Street maintaining bullish ratings despite recent earnings volatility. The AI pivot and potential chip unit IPO offer growth catalysts, but declining profitability and negative cash flows pose substantial risks. Investors should weigh strong balance sheet strength against execution challenges in China's competitive tech landscape.
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
